Osaka Metropolitan University Hospital is a university hospital in Japan. It's located in Abeno-ku, Osaka, and affiliated with Osaka Metropolitan University.

There are 980 beds in Osaka City University Hospital.

During the past decade, Osaka City University Hospital conducted 79 clinical trials. In the 10-year time frame, 79 clinical trials started and 53 clinical trials were completed, i.e. on average, 67.1% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 36 clinical trials were completed. i.e. 102.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka City University Hospital" #1 sponsor was "Pfizer" with 20 trials, followed by "Celgene" with 14 trials sponsored, "Eli Lilly and Company" with 10 trials sponsored, "Janssen Research & Development, LLC" with 6 trials sponsored and "Boehringer Ingelheim" with 6 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 37 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka City University Hospital" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Osaka City University Hospital" are "Ulcerative Colitis" (8 trials), "Crohn's Disease" (7 trials), "Alopecia Areata" (4 trials), "Alzheimer Disease" (3 trials) and "Leukemia, Myeloid, Acute" (3 trials). Many other conditions were trialed in "Osaka City University Hospital" in a lesser frequency.

Most popular intervention types in "Osaka City University Hospital" are "Drug" (87 trials), "Biological" (11 trials), "Other" (10 trials), "Device" (5 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "CP-690,550" (5 trials), "Baricitinib" (4 trials), "Filgotinib" (4 trials) and "Guselkumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Osaka City University Hospital" are 101 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Osaka City University Hospital". undefined are not yet recruiting, 19 are recruiting, 15 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 58 completed trials in Osaka City University Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Osaka City University Hospital, 8 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 71 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".